Preclinical Evaluation of a New Anti-COVID-19 Intravenous Immunoglobulin

Introduction. Using of immunoglobulins containing SARS-CoV-2 neutralizing antibodies may be an effective and safe tool for COVID-19 treatment. An intravenous immunoglobulin COVID-globulin from donor blood plasma containing SARS-CoV-2 neutralizing antibodies was developed at Joint-Stock Company Nacimbio.

Aim. A pilot study of the safety of the "COVID-globulin".

Materials and methods. When studying the safety of the preparation in animals the following parameters were evaluated: general toxicity, thrombogenic potential, influence on hematological and biochemical parameters, blood clotting and hemolytic activity, determination of local irritant action, pyrogenic properties, bacterial endotoxins, allergic effect of the drug preparation and its physicochemical characteristics.

Results and discussion. Safety studies of "COVID-globulin" in animals showed no signs of intoxication, local irritant action and thrombogenic properties. Macroscopic and histological examination of the organs of rats treated with COVID-globulin showed no signs of necrosis, inflammation, atypia, or any significant pathological changes. Hematological and biochemical parameters of the blood of laboratory animals after the administration of "COVID-globulin" corresponded to the reference values. Administration of COVID-globulin to rabbits did not activate blood clot formation. The IgG subclasses distribution in the preparation corresponded to that in human plasma. The activity of the Fc-function of the immunoglobulin molecule was more than 130 % compared to the reference standard preparation, the concentration of the prekallikrein activator in the COVID-globulin ranged from 4.2 to 4.8 IU/ml, anticomplementary activity was less than 1 unit complement per 1 mg of protein.

Conclusion. The results of all studies have demonstrated a high level of safety of the developed COVID-globulin preparation, which meets the safety requirements for human immunoglobulins for intravenous administration by national regulatory documents and the European Pharmacopoeia.

1. Rojas M., Rodríguez Y., Monsalve D. M., Acosta-Ampudia Y., Camacho B., Gallo J. E., Rojas-Villarraga A., Ramírez-Santana C., Díaz-Coronado J. C., Manrique R., Mantilla R. D., Shoenfeld Y., Anaya J. M. Convalescent plasma in Covid-19: Possible mechanisms of action. Autoimmunity Reviews. 2020;19(7):102554. DOI: 10.1016/j.autrev.2020.102554.

2. Jiang S., Du L., Shi Z. An emerging coronavirus causing pneumonia outbreak in Wuhan China: calling for developing therapeutic and prophylactic strategies. Emerging Microbes & Infections. 2020;9(1):275–277. DOI: 10.1080/22221751.2020.1723441.

3. Zakharov V. V., Afonin N. I. Safety of blood transfusion therapy. Vestnik sluzhby krovi Rossii. 2006;3(09):6–12. (In Russ.)

4. Mironov A. N. Guidelines for Preclinical Trials of Medicinal Products. Part 2. Moscow: Grif i K; 2012. 536 p. (In Russ.)

5. Wessler S., Reiner S. M., Sheps M. C. Biologic assay of a thrombosis-inducing activity in human serum. Journal of applied physiology. 1959;14:943–946.